YIV-906
- Generic Name
- YIV-906
A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2019-05-22
- Lead Sponsor
- Edward Chu, MD
- Target Recruit Count
- 33
- Registration Number
- NCT00730158
- Locations
- 🇺🇸
Yale University Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸Hillman CancerCenters, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath